Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses

Vaccine

Volumn 26, Issue 21, 2008, Pages 2627-2639

  Holman, David H ^a   Wang, Danher ^a   Raja, Nicholas U ^a   Luo, Min ^a   Moore, Kevin M ^a   Woraratanadharm, Jan ^a   Mytle, Nutan ^c   Dong, John Y ^a,b  

^a GenPhar Inc   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adenovirus; H5N1; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BODY WEIGHT; GENETIC VECTORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 42749085687     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.053     Document Type: Article

References (39)

1. Anonymous. Pandemics and pandemic threats since 1900. Department of Health and Human Services (www.pandemicflu.gov); 2006.
2. Reid A.H., Taubenberger J.K., and Fanning T.G. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol 2 11 (2004) 909-914
3. Taubenberger J.K., Reid A.H., Lourens R.M., Wang R., Jin G., and Fanning T.G. Characterization of the 1918 influenza virus polymerase genes. Nature 437 7060 (2005) 889-893
4. Anonymous. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. World Health Organization (www.who.int/en/); 2007.
5. Taubenberger J.K., Reid A.H., Krafft A.E., Bijwaard K.E., and Fanning T.G. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 275 5307 (1997) 1793-1796
6. Shinya K., Ebina M., Yamada S., Ono M., Kasai N., and Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 440 7083 (2006) 435-436
7. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 102 36 (2005) 12915-12920 [Epub 2005 Aug 23]
8. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
9. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215 [Epub 2005 Mar 14]
10. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 15 (2003) 1687-1693
11. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732-1737
12. Kodihalli S., Goto H., Kobasa D.L., Krauss S., Kawaoka Y., and Webster R.G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73 3 (1999) 2094-2098
13. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 80 Pt 10 (1999) 2559-2564
14. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80 4 (2006) 1959-1964
15. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 9509 (2006) 475-481
16. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 46-47 (2005) 5404-5410 [Epub 2005 Jun 13]
17. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13 3 (2007) 426-435
18. Toro H., Tang D.C., Suarez D.L., Sylte M.J., Pfeiffer J., and Van Kampen K.R. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 25 15 (2007) 2886-2891 [Epub 2006 Sep 25]
19. Rubinchik S., Norris J.S., and Dong J.Y. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol 346 (2002) 529-547
20. Rubinchik S., Woraratanadharm J., Schepp J., and Dong J.Y. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods Mol Med 76 (2003) 167-199
21. Holman D.H., Wang D., Raviprakash K., Raja N.U., Luo M., Zhang J., et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 14 2 (2007) 182-189 [Epub 2006 Dec 27]
22. Wang D., Schmaljohn A.L., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine 24 15 (2006) 2975-2985
23. Wang D., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., Woraratanadharm J., et al. Development of a cAdVax-based bivalent Ebola vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 80 6 (2006) 2738-2746
24. Liu F., Mboudjeka I., Shen S., Chou T.H., Wang S., Ross T.M., et al. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine 22 13-14 (2004) 1764-1772
25. Li S., Locke E., Bruder J., Clarke D., Doolan D.L., Havenga M.J., et al. Viral vectors for malaria vaccine development. Vaccine (2006) [August 1, 2006 E-pub]
26. Lin C.T., Tsai Y.C., He L., Calizo R., Chou H.H., Chang T.C., et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 13 4 (2006) 481-488 [Epub 2006 Apr 29]
27. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
28. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
29. Wang D., Hevey M., Juompan L.Y., Trubey C.M., Raja N.U., Deitz S.B., et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 353 2 (2006) 324-332
30. Raja N.U., Holman D.H., Wang D., Raviprakash K., Juompan L.Y., Deitz S.B., et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am J Trop Med Hyg 76 4 (2007) 743-751
31. Schepp-Berglind J., Luo M., Wang D., Wicker J.A., Raja N., Hoel B., et al. Complex adenovirus-mediated expression of C, PreM, E, and NS1 proteins of West Nile Virus induces both humoral and cellular immune responses. Clin Vac Immunol 14 9 (2007) 1117-1126
32. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 8 (2005) 1029-1036
33. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 2 (2004) 351-357
34. Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Ruggeri L., et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 80 4 (2006) 1688-1699
35. Hashimoto M., Boyer J.L., Hackett N.R., Wilson J.M., and Crystal R.G. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immunol 73 10 (2005) 6885-6891
36. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346 2 (2006) 394-401 [Epub 2005 Dec 13]
37. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77 20 (2003) 10780-10789
38. Cohen P. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep 10 1 (2006) 1-5
39. Appaiahgari M.B., Saini M., Rauthan M., Jyoti, and Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8 1 (2006) 92-104 [Epub 2005 Aug 9]